Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Apr;69(4):332–337. doi: 10.1136/hrt.69.4.332

Beta adrenoreceptor subtype cross regulation in the human heart.

J A Hall 1, A Ferro 1, J E Dickerson 1, M J Brown 1
PMCID: PMC1025047  PMID: 8098220

Abstract

OBJECTIVES--To find out in a prospective study whether beta 1 blocker treatment causes selective beta 2 adrenoreceptor sensitisation, and to find whether such sensitisation is confined to the heart. DESIGN--A placebo controlled cross over study of two weeks of selective beta 1 blocker treatment with 10 mg of bisoprolol daily. SUBJECTS--Six healthy volunteers. OUTCOME MEASURES--Three days after stopping the 10 mg of bisoprolol or placebo, subjects underwent treadmill exercise (to measure cardiac beta 1 receptor responsiveness) and were given salbutamol injections (to measure cardiac beta 2 receptor responsiveness). Secondary end points were the responses of serum potassium, glucose, and insulin to beta 2 stimulation. RESULTS--There was no difference in exercise induced increases in heart rate, but after treatment with bisoprolol the dose of salbutamol required to increase heart rate by 40 beats/min was 1.9 micrograms/kg compared with 2.9 micrograms/kg after placebo (p < 0.005). The fall in diastolic blood pressure was not significantly different on the two occasions. Hypokalaemia induced by salbutamol, but not hyperglycaemia or hyperinsulinaemia, was enhanced after bisoprolol. CONCLUSION--This study shows that treatment with a beta 1 blocker in vivo leads to sensitisation of cardiac beta 2 adrenoreceptors but not cardiac beta 1 adrenoreceptors or vascular beta 2 receptors. This previously unrecognised form of receptor cross sensitisation in the heart may noticeably diminish the efficacy of selective beta 1 blockade in preventing arrhythmias in patients with ischaemic heart disease. These findings reopen the question of which type of beta blocker is more appropriate for such patients.

Full text

PDF
332

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berend N., Marlin G. E. Characterization of beta-adrenoceptor subtype mediating the metabolic actions of salbutamol. Br J Clin Pharmacol. 1978 Mar;5(3):207–211. doi: 10.1111/j.1365-2125.1978.tb01625.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bree F., Gault I., d'Athis P., Tillement J. P. Beta adrenoceptors of human red blood cells, determination of their subtypes. Biochem Pharmacol. 1984 Dec 15;33(24):4045–4050. doi: 10.1016/0006-2952(84)90019-4. [DOI] [PubMed] [Google Scholar]
  3. Brown M. J., Brown D. C., Murphy M. B. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414–1419. doi: 10.1056/NEJM198312083092303. [DOI] [PubMed] [Google Scholar]
  4. Clausen T., Flatman J. A. Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle. Br J Pharmacol. 1980 Apr;68(4):749–755. doi: 10.1111/j.1476-5381.1980.tb10868.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davies A. O., Su C. J., Balasubramanyam A., Codina J., Birnbaumer L. Abnormal guanine nucleotide regulatory protein in MVP dysautonomia: evidence from reconstitution of Gs. J Clin Endocrinol Metab. 1991 Apr;72(4):867–875. doi: 10.1210/jcem-72-4-867. [DOI] [PubMed] [Google Scholar]
  6. Green A. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem. 1987 Nov 15;262(32):15702–15707. [PubMed] [Google Scholar]
  7. Hall J. A., Kaumann A. J., Brown M. J. Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium. Circ Res. 1990 Jun;66(6):1610–1623. doi: 10.1161/01.res.66.6.1610. [DOI] [PubMed] [Google Scholar]
  8. Hall J. A., Petch M. C., Brown M. J. In vivo demonstration of cardiac beta 2-adrenoreceptor sensitization by beta 1-antagonist treatment. Circ Res. 1991 Oct;69(4):959–964. doi: 10.1161/01.res.69.4.959. [DOI] [PubMed] [Google Scholar]
  9. Hall J. A., Petch M. C., Brown M. J. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart. Circ Res. 1989 Sep;65(3):546–553. doi: 10.1161/01.res.65.3.546. [DOI] [PubMed] [Google Scholar]
  10. John G. W., Doxey J. C., Walter D. S., Reid J. L. The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat. Br J Pharmacol. 1990 Aug;100(4):699–704. doi: 10.1111/j.1476-5381.1990.tb14078.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaumann A. J., Sanders L., Brown A. M., Murray K. J., Brown M. J. A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol. 1990 Aug;100(4):879–885. doi: 10.1111/j.1476-5381.1990.tb14108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lands A. M., Arnold A., McAuliff J. P., Luduena F. P., Brown T. G., Jr Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967 May 6;214(5088):597–598. doi: 10.1038/214597a0. [DOI] [PubMed] [Google Scholar]
  13. Michel M. C., Pingsmann A., Beckeringh J. J., Zerkowski H. R., Doetsch N., Brodde O. E. Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment. Br J Pharmacol. 1988 Jul;94(3):685–692. doi: 10.1111/j.1476-5381.1988.tb11576.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neumann J., Schmitz W., Scholz H., von Meyerinck L., Döring V., Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988 Oct 22;2(8617):936–937. doi: 10.1016/s0140-6736(88)92601-3. [DOI] [PubMed] [Google Scholar]
  15. Norris R. M., Barnaby P. F., Brown M. A., Geary G. G., Clarke E. D., Logan R. L., Sharpe D. N. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet. 1984 Oct 20;2(8408):883–886. doi: 10.1016/s0140-6736(84)90651-2. [DOI] [PubMed] [Google Scholar]
  16. Pollare T., Lithell H., Selinus I., Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989 Apr 29;298(6681):1152–1157. doi: 10.1136/bmj.298.6681.1152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Prichard B. N., Tomlinson B., Walden R. J., Bhattacharjee P. The beta-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S56–S62. doi: 10.1097/00005344-198300051-00009. [DOI] [PubMed] [Google Scholar]
  18. Pringle T. H., Riddell J. G., Shanks R. G. Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol. 1988;35(5):507–514. doi: 10.1007/BF00558246. [DOI] [PubMed] [Google Scholar]
  19. Reithmann C., Gierschik P., Sidiropoulos D., Werdan K., Jakobs K. H. Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein alpha-subunits. Eur J Pharmacol. 1989 Aug 15;172(3):211–221. doi: 10.1016/0922-4106(89)90051-5. [DOI] [PubMed] [Google Scholar]
  20. Stiles G. L., Taylor S., Lefkowitz R. J. Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci. 1983 Aug 1;33(5):467–473. doi: 10.1016/0024-3205(83)90796-8. [DOI] [PubMed] [Google Scholar]
  21. Struthers A. D., Reid J. L., Whitesmith R., Rodger J. C. The effects of cardioselective and non-selective beta-adrenoceptor blockade on the hypokalaemic and cardiovascular responses to adrenomedullary hormones in man. Clin Sci (Lond) 1983 Aug;65(2):143–147. doi: 10.1042/cs0650143. [DOI] [PubMed] [Google Scholar]
  22. Sumner D. J., Elliott H. L., Reid J. L. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. doi: 10.1038/clpt.1982.188. [DOI] [PubMed] [Google Scholar]
  23. Tattersfield A. E., Cragg D. J. Effect of ICI 118551 on bronchial beta-adrenoceptor function and exercise heart rate in normal man. Br J Clin Pharmacol. 1983 Dec;16(6):587–590. doi: 10.1111/j.1365-2125.1983.tb02226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vincent H. H., Boomsma F., Man in't Veld A. J., Derkx F. H., Wenting G. J., Schalekamp M. A. Effects of selective and nonselective beta-agonists on plasma potassium and norepinephrine. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):107–114. [PubMed] [Google Scholar]
  25. Wellstein A., Belz G. G., Palm D. Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots. J Pharmacol Exp Ther. 1988 Jul;246(1):328–337. [PubMed] [Google Scholar]
  26. Wellstein A., Palm D., Belz G. G., Butzer R., Polsak R., Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J. 1987 Dec;8 (Suppl 1000):3–8. doi: 10.1093/eurheartj/8.suppl_m.3. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES